Global Sideroblastic Anemia Market, By Drug Class (Oral Pyridoxine, Iron Chelation, Deferoxamine or Oral Chelators, Others), Treatment (Drugs, Blood Transfusion, Phlebotomy, Others), Symptoms (Fatigue, Weakness, Palpitations, Shortness Of Breath, Headaches, Irritability, Chest Pain, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.
Sideroblastic Anemia Market Analysis and Size
Sideroblastic anemia refers to a form of anemia that is caused due to the abnormal utilization of iron during erythropoiesis. The various forms of sideroblastic anemia are generally described as the presence of ring sideroblasts in the bone marrow. Ring sideroblasts are defined as the erythroid precursors possessing deposits of non-heme iron in mitochondria that form a ring-like distribution around the nucleus. The iron-formed ring covers at least one-third of the nucleus rim.
The increase in the number of people suffering from sideroblastic anemia across the globe acts as one of the major factors driving the growth of global sideroblastic anemia market. The rise in the demand for drugs such as pyridoxine for patients diagnosed with the X-linked sideroblastic anemia and development of technology offering therapies for treating various complications caused by the disorder accelerate the market growth. The surge in in the number of acquisition strategies and company collaborations among manufacturers to develop new drugs and growth in awareness regarding the anemic related disorders further influence the market. Additionally, growing population, developing healthcare infrastructure and technology, and increase in investments for the research activities positively affect the global sideroblastic anemia market.
Data Bridge Market Research analyses that the global sideroblastic anemia market which was USD 4.17 billion in 2022, would rocket up to USD 7.07 billion by 2030, and is expected to undergo a CAGR of 6.9% during the forecast period 2023-2030. This indicates that the market value. “Hospitals” dominates the end user segment of the global sideroblastic anemia market owing to rise in the aging population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Sideroblastic Anemia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Oral Pyridoxine, Iron Chelation, Deferoxamine or Oral Chelators, Others), Treatment (Drugs, Blood Transfusion, Phlebotomy, Others), Symptoms (Fatigue, Weakness, Palpitations, Shortness Of Breath, Headaches, Irritability, Chest Pain, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others).
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa
|
|
Market Players Covered
|
Eisai Co. Ltd. (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Teva Pharmaceuticals Industries Ltd. (Israel), Novartis AG (Switzerland), Allergan (Ireland), Merz Pharma (Germany), Johnson & Johnson Services, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), AbbVie Inc. (U.S.), Lilly (Eli Lilly and Company) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Germany), Biogen (U.S.), AstraZeneca (U.K.), VTV Therapeutics (U.S.), H. Lundbeck A/S (Denmark), TauRx Pharmaceuticals Ltd (U.K.), and DAIICHI SANKYO COMPANY, LIMITED (Japan)
|
|
Market Opportunities
|
|
Market Definition
Sideroblastic anemia refers to a form of anemia that is caused due to the abnormal utilization of iron during erythropoiesis. The various forms of sideroblastic anemia are generally described as the presence of ring sideroblasts in the bone marrow. Ring sideroblasts are defined as the erythroid precursors possessing deposits of non-heme iron in mitochondria that form a ring-like distribution around the nucleus. The iron-formed ring covers at least one-third of the nucleus rim.
Global Sideroblastic Anemia Market Dynamics
Drivers
- Genetic Research and Precision Medicine
Researchers have made significant progress in understanding the genetic mutations and pathways associated with sideroblastic anemia. This knowledge has opened the door to the development of targeted therapies and personalized treatment options, driving research and investment in the field.
- Advancements in Diagnostic Techniques
Many Technological advancements in diagnostic tools, such as genetic testing and molecular profiling, have made it easier to identify and classify different forms of sideroblastic anemia. This has enabled more accurate diagnosis and targeted treatment strategies.
Opportunity
- Rare Disease Research and Orphan Drug Designation
Sideroblastic anemia is considered a rare disease. Companies that focus on orphan drug development might find opportunities in this market, as governments and regulatory bodies often provide incentives and exclusivity for drugs targeting rare diseases.
Restraint/Challenge
- Lack of Standardized Treatment
There is no standard treatment protocol for sideroblastic anemia, which can lead to variations in care and uncertainty in treatment outcomes.
This global sideroblastic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global sideroblastic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Sideroblastic Anemia Market Scope
Global sideroblastic anemia market is categorized into six notable segments which are based on the basis of drug class, treatment, symptoms, mode of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Oral Pyridoxin
- Iron Chelation
- Deferoxamine
- Oral Chelators
- Others
Treatment
- Drugs
- Blood Transfusion
- Phlebotomy
- Others
Symptoms
- Fatigue
- Weakness
- Palpitations
- Shortness of Breath
- Headaches
- Irritability
- Chest Pain
- Others
Mode of Administration
- Injectable
- Oral
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User
- Homecare
- Speciality
- Hospitals
- Clinics
- Others
Global Sideroblastic Anemia Market Regional Analysis/Insights
The global sideroblastic anemia market is analyzed and market size information is provided by country, drug class, treatment, symptoms, mode of administration, distribution channel and end user as referenced above.
The countries covered in the global sideroblastic anemia market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the global sideroblastic anemia market due to increased drug approvals and well-established healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the developing health care infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global sideroblastic anemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global sideroblastic anemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global sideroblastic anemia market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Sideroblastic Anemia Market Share Analysis
Global sideroblastic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global sideroblastic anemia market.
Some of the major players operating in the global sideroblastic anemia market are:
- Eisai Co. Ltd. (Japan)
- Pfizer, Inc. (U.S.)
- Sanofi (France)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Novartis AG (Switzerland)
- Allergan (Ireland)
- Merz Pharma (Germany)
- Johnson & Johnson Services, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- AbbVie Inc. (U.S.)
- Lilly Eli Lilly and Company (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Bayer AG (Germany)
- Biogen (U.S.)
- AstraZeneca (U.K.)
- VTV Therapeutics (U.S.)
- H. Lundbeck A/S (Denmark)
- TauRx Pharmaceuticals Ltd (U.K.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
SKU-